🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
2025-524384-20-00Atopic dermatitis (AD)
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia
18/09/2026
Phase II
Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
2026-526857-33-00liver cirrhosis and hepatocellular carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neoplasms
Italy
17/09/2026
Phase II
BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma
2025-521749-26-00Advanced Stage Classic Hodgkin Lymphoma
University Of Cologne
Hemic and Lymphatic Diseases
Germany
17/09/2026
Phase II
The Role of Serotonin 4 Receptor Agonism in Regulating Mood and Cognition in Depression in women (RECAP-D)
2026-526685-25-00Major depressive disorder
Region Hovedstaden
Mental Disorders
Denmark
17/09/2026
Phase II
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00Non Small Cell Lung Cancer (NSCLC)
Oslo Universitetssykehus HF
Neoplasms
Sweden, Norway
16/09/2026
Phase II
A single-centre, Phase 2, open-label study to investigate ovulation inhibition after the administration of different dosages of dienogest tablets in combination with different dosages of drospirenone tablets with regular intake and after intentional intake errors in healthy premenopausal female participants
2026-526788-39-00Contraception/Pregnancy prevention in healthy subjects
Gedeon Richter Plc.
Reproductive and Urinary Physiological Phenomena
Germany
16/09/2026
Phase II
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
2026-526207-30-00End stage kindey disease
Aplagon Oy
Not possible to specify
Sweden, Spain, Finland
15/09/2026
Phase II
Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00Acute lymphoblastic leukaemia
Fundacion PETHEMA
Neoplasms
Spain
15/09/2026
Phase II
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00Pulmonary Disease, Chronic Obstructive
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany
15/09/2026
Phase II
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
2025-524655-30-00Parkinson’s disease
H. Lundbeck A/S
Nervous System Diseases
Czechia, Spain, Italy, Germany, Sweden
15/09/2026
Phase II
Optimization of De-EscalatiON strategies in early breast cancer
2026-527524-27-00breast cancer
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Neoplasms
Italy
14/09/2026
Phase II
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)
2025-524496-23-00Papulopustular Rosacea (PPR)
Novartis Pharma AG
Skin and Connective Tissue Diseases
Bulgaria, France, Italy, Germany
14/09/2026
Phase II
COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…
Unicancer
Neoplasms
France
11/09/2026
Phase II
Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial
2026-525680-41-00Vascular Calcification
Radboud universitair medisch centrum Stichting
Therapeutics
Netherlands
11/09/2026
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00Atopic Dermatitis
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia
10/09/2026
Phase II
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
2026-525445-73-00TMB-high advanced neoplasms
UZ Brussel
Neoplasms
Belgium
09/09/2026
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight
2026-526951-79-00Body weight management
Camurus AB
Nutritional and Metabolic Diseases
Germany
09/09/2026
Phase II
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
Immune System Diseases
Germany, Romania, Italy, Slovakia, Spain
09/09/2026
Phase II
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
2026-526218-10-00Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (S…
Argenx
Immune System Diseases
Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria
08/09/2026
Phase II
SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men
2026-527538-29-00Infertility, overweight
Region Hovedstaden
Male Urogenital Diseases
Denmark
08/09/2026
Phase II
Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)
2025-523414-89-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
08/09/2026
Phase II
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Italy, Spain, Romania, Germany, France
07/09/2026
Phase II
"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"
2026-526530-13-00Intracranial aneurysms
Centre Hospitalier Universitaire De Bordeaux
Nervous System Diseases
France
07/09/2026
Phase II
Phase 2, randomized, blinded, non-treatment-controlled study assessing the efficacy and safety of dimethyl fumarate in patients with NBIA, a neurodegeneration associated with brain iron accumulation.
2026-525990-38-00Neurodegeneration with brain iron accumulation (NBIA), incl…
Instytut Psychiatrii I Neurologii
Nervous System Diseases
Poland
07/09/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
2025-524104-30-00Tardive Dyskinesia
Neurocrine Biosciences Inc.
Nervous System Diseases
Bulgaria, Croatia, Romania, Slovakia, Czechia
07/09/2026
Rows per page Showing 1–25 of 726
1 2 3 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.